Shi Nian-Qiu, Yao Jing, Wang Xing-Lin
The State Key Laboratories of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research , Tianjin , P.R. China and.
Drug Dev Ind Pharm. 2014 Aug;40(8):1112-22. doi: 10.3109/03639045.2013.809536. Epub 2013 Jun 28.
Amorphous forms of crystalline drug are widely utilized for bioavailability enhancement of low solubility drugs in the pharmaceutical industry. Polymers have been found to be effective crystallization inhibitors for amorphous forms in solid states during storage or in liquid states during dissolution process. The dissolution and crystallization behaviors of these amorphous forms in the presence or absence of polymers are still far from adequately understood especially in different dissolution environments. The objective of this study was to investigate the effects of polymers and media type on extending the dissolution of amorphous pioglitazone and inhibiting the recrystallization from a supersaturated state. Polyvinylpyrrolidone K30 (PVPK30), polyvinylpyrrolidone K90 (PVPK90), polyethylene glycol 6000 (PEG6000), polyethylene-polypropylene glycol 188 (F-68), hydroxypropylmethylcellulose (HPMC) and beta-cyclodextrin (β-CD) were employed to understand these behaviors changes because these polymers were used widely. Three solutions including neutral water and phosphate buffer solutions (PBS, pH6.8 and pH7.4) were adopted as dissolution media to determine the behaviors changes comprehensively. In the presence of polymers, dissolution and solubility were extended to different degrees in three media. Polymers can delay the crystallization routes dependently of the medium type. Buffer salts in media reduced the dissolution and accelerated the crystallization process. Crystallization inhibition of these polymers was strongly dependent on the type and pH of media. HPMC displayed the strongest crystallization inhibition effects, resulting in the greatest degree of maintaining a supersaturated state that can sustain most effectively for biologically relevant timeframes.
在制药行业中,结晶药物的无定形形式被广泛用于提高低溶解度药物的生物利用度。人们发现聚合物在储存期间作为固态无定形形式或溶解过程中作为液态无定形形式的有效结晶抑制剂。尤其是在不同的溶解环境中,这些无定形形式在有无聚合物存在下的溶解和结晶行为仍远未得到充分理解。本研究的目的是研究聚合物和介质类型对延长无定形吡格列酮的溶解以及抑制从过饱和状态重结晶的影响。使用聚乙烯吡咯烷酮K30(PVPK30)、聚乙烯吡咯烷酮K90(PVPK90)、聚乙二醇6000(PEG6000)、聚乙丙二醇188(F-68)、羟丙基甲基纤维素(HPMC)和β-环糊精(β-CD)来了解这些行为变化,因为这些聚合物被广泛使用。采用三种溶液,包括中性水和磷酸盐缓冲溶液(PBS,pH6.8和pH7.4)作为溶解介质,以全面确定行为变化。在聚合物存在下,三种介质中的溶解和溶解度在不同程度上得到延长。聚合物可根据介质类型延迟结晶途径。介质中的缓冲盐降低了溶解并加速了结晶过程。这些聚合物的结晶抑制作用强烈依赖于介质的类型和pH值。HPMC表现出最强的结晶抑制作用,导致在生物相关时间范围内能最有效地维持过饱和状态的程度最大。